Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery.

The aim of this study was to characterize nanoparticles (NPs) composed of chitosan (CS) and evaluate their potential for brain delivery of the neurotransmitter Dopamine (DA). For this purpose, CS based NPs were incubated with DA at two different concentrations giving rise to nanocarriers denoted as DA/CSNPs (1) and DA/CSNPs (5), respectively. X-ray Photoelectron Spectroscopy (XPS) analysis confirmed that DA was adsorbed onto the external surface of such NPs. The cytotoxic effect of the CSNPs and DA/CSNPs was assessed using the MTT test and it was found that the nanovectors are less cytotoxic than the neurotransmitter DA after 3 h of incubation time. Transport studies across MDCKII-MDR1 cell line showed that DA/CSNPs (5) give rise to a significant transport enhancing effect compared with the control and greater than the corresponding DA/CSNPs (1). Measurement of reactive oxygen species (ROS) suggested a low DA/CSNPs neurotoxicity after 3 h. In vivo brain microdialysis experiments in rat showed that intraperitoneal acute administration of DA/CSNPs (5) (6-12 mg/kg) induced a dose-dependent increase in striatal DA output. Thus, these CS nanoparticles represent an interesting technological platform for DA brain delivery and, hence, may be useful for Parkinson's disease treatment.

[1]  K. Jellinger,et al.  Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[2]  N. Cioffi,et al.  A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  A. Trapani,et al.  Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan , 2008, Nanotechnology.

[4]  H. M. Swartz,et al.  The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[5]  V. Pillay,et al.  Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. , 2009, International journal of pharmaceutics.

[6]  J. Liao,et al.  Dual properties of the deacetylated sites in chitosan for molecular immobilization and biofunctional effects. , 2005, Biomacromolecules.

[7]  P. Gaillard,et al.  Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[9]  N. Cioffi,et al.  Analytical characterization of chitosan nanoparticles for peptide drug delivery applications , 2009, Analytical and bioanalytical chemistry.

[10]  Wei Sun,et al.  Chitosan-based formulations for delivery of DNA and siRNA. , 2010, Advanced drug delivery reviews.

[11]  Julen Oyarzabal,et al.  In vivo, in vitro and in silico methods for small molecule transfer across the BBB. , 2009, Journal of pharmaceutical sciences.

[12]  J. Scherrmann,et al.  CNS Delivery Via Adsorptive Transcytosis , 2008, The AAPS Journal.

[13]  M. J. Santander-Ortega,et al.  Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. , 2006, Journal of colloid and interface science.

[14]  Dezhen Wu,et al.  A facile method for preparing highly conductive and reflective surface-silvered polyimide films , 2009 .

[15]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[16]  María J Alonso,et al.  Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). , 2007, Biomaterials.

[17]  G. Biggio,et al.  Novel L-Dopa and Dopamine Prodrugs Containing a 2-Phenyl-imidazopyridine Moiety , 2007, Pharmaceutical Research.

[18]  R. Makuška,et al.  Synthesis and properties of chitosan-N-dextran graft copolymers , 2008 .

[19]  M. O'Neill,et al.  6-Hydroxydopamine-induced Apoptosis Is Mediated via Extracellular Auto-oxidation and Caspase 3-dependent Activation of Protein Kinase Cδ* , 2006, Journal of Biological Chemistry.

[20]  A. Di Stefano,et al.  Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties. , 2007, Journal of medicinal chemistry.

[21]  M. Garcia‐Fuentes,et al.  A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  R. Müller,et al.  Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles , 2001, Journal of microencapsulation.

[23]  A. Raasmaja,et al.  A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[24]  T. Cassano,et al.  Monoaminergic Changes in Locus Coeruleus and Dorsal Raphe Nucleus Following Noradrenaline Depletion , 2009, Neurochemical Research.

[25]  S. Rossi,et al.  Chitosan citrate as multifunctional polymer for vaginal delivery. Evaluation of penetration enhancement and peptidase inhibition properties. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  D. Paolino,et al.  Supramolecular devices to improve the treatment of brain diseases. , 2011, Drug discovery today.

[27]  M. Garcia‐Fuentes,et al.  The performance of nanocarriers for transmucosal drug delivery , 2006, Expert opinion on drug delivery.

[28]  Rakesh K. Sharma,et al.  Pharmacoscintigraphic evaluation of polysorbate80-coated chitosan nanoparticles for brain targeting , 2005 .

[29]  K. Janes,et al.  Chitosan nanoparticles as delivery systems for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[30]  J. Hwang,et al.  N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[31]  C. Remuñán-López,et al.  Microencapsulated chitosan nanoparticles for lung protein delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  Yong Hu,et al.  Hollow chitosan/poly(acrylic acid) nanospheres as drug carriers. , 2007, Biomacromolecules.

[33]  R. Pahwa,et al.  Advances in the treatment of Parkinson's disease. , 1998, Drugs of today.

[34]  K. Janes,et al.  Polysaccharide colloidal particles as delivery systems for macromolecules. , 2001, Advanced drug delivery reviews.

[35]  A. Trapani,et al.  The use of Eudragit RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[36]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.